Patient Support
Genentech wants to help your patients with rheumatoid arthritis (RA) get the information and support necessary for managing RA and accessing ACTEMRA. We've provided the ACTEMRA patient brochure below. We encourage you to download the brochure and share it with your patients.
The patient support program
ACTiV — Our patient support program — is an online resource for people with RA who have been prescribed ACTEMRA. ACTiV offers online tools that can help your patients manage RA, including:
Appointment Calendar
Patients can use this helpful tool to add important events like rheumatologist and infusion appointments to an online calendar and then receive convenient reminder emails alerting them prior to their appointments.
Recipes
Your patients will have access to many simple and healthy recipes that were created for people living with chronic pain.
Exercises
These gentle stretching exercises and easy aerobic activities can help your patients stay motivated and improve their health and mobility.
INDICATION
ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
IMPORTANT SAFETY INFORMATION
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.
ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA.
- If anaphylaxis or other clinically significant hypersensitivity reaction occurs, administration of ACTEMRA should be stopped immediately and ACTEMRA should be permanently discontinued.
Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions. Other potential risks of ACTEMRA include demyelinating disorders, malignancies, and changes to certain lab parameters.
Common adverse reactions include upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.
Please see full Prescribing Information including Boxed Warning for additional important safety information.
The resource above is provided in Adobe® Reader® format (PDF). To view or print, you must have Adobe Reader (version 3.0 or higher) installed on your computer. Download the free Adobe Reader here.
